Paper37587481
MicroRNAs as the pivotal regulators of cisplatin resistance in head and neck cancers.
Tolue Ghasaban F and 4 others. Cancer Cell Int, 2023. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. MicroRNAs as the pivotal regulators of cisplatin resistance in head and neck cancers. Papers, record 37587481. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37587481
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References168
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23258613 | The role of human papillomavirus in nongenital cancers. | CA Cancer J Clin | 2013 | https://conductscience.org/library/papers/23258613 | PubMed |
| 2 | 27245686 | Global Epidemiology of Head and Neck Cancers: A Continuing Challenge. | Oncology | 2016 | https://conductscience.org/library/papers/27245686 | PubMed |
| 3 | 32017286 | Tumor immune microenvironment in head and neck cancers. | Mol Carcinog | 2020 | https://conductscience.org/library/papers/32017286 | PubMed |
| 4 | 30207593 | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2018 | https://conductscience.org/library/papers/30207593 | PubMed |
| 5 | 32209823 | Epidemiology of head and neck cancers: an update. | Curr Opin Oncol | 2020 | https://conductscience.org/library/papers/32209823 | PubMed |
| 6 | 31893516 | Head and Neck Cancer. | N Engl J Med | 2020 | https://conductscience.org/library/papers/31893516 | PubMed |
| 7 | 25313184 | Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. | J Natl Compr Canc Netw | 2014 | https://conductscience.org/library/papers/25313184 | PubMed |
| 8 | 30082187 | The role of tumor DNA as a diagnostic tool for head and neck squamous cell carcinoma. | Semin Cancer Biol | 2019 | https://conductscience.org/library/papers/30082187 | PubMed |
| 9 | 29355614 | Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. | Semin Cancer Biol | 2018 | https://conductscience.org/library/papers/29355614 | PubMed |
| 10 | 25220842 | Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. | Int J Cancer | 2015 | https://conductscience.org/library/papers/25220842 | PubMed |
| 11 | 31003864 | Platinum rechallenge in recurrent head and neck squamous cell carcinoma after primary chemoradiation. | Eur Ann Otorhinolaryngol Head Neck Dis | 2019 | https://conductscience.org/library/papers/31003864 | PubMed |
| 12 | 34099061 | MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells. | Genes Environ | 2021 | https://conductscience.org/library/papers/34099061 | PubMed |
| 13 | 21892204 | Molecular mechanisms of cisplatin resistance. | Oncogene | 2012 | https://conductscience.org/library/papers/21892204 | PubMed |
| 14 | 30847300 | Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer. | Front Oncol | 2019 | https://conductscience.org/library/papers/30847300 | PubMed |
| 15 | 31750863 | Predicting Hearing Loss After Radiotherapy and Cisplatin Chemotherapy in Patients With Head and Neck Cancer. | JAMA Otolaryngol Head Neck Surg | 2020 | https://conductscience.org/library/papers/31750863 | PubMed |
| 16 | 31150573 | Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31150573 | PubMed |
| 17 | 23148615 | Epigenetic mechanisms in oral carcinogenesis. | Future Oncol | 2012 | https://conductscience.org/library/papers/23148615 | PubMed |
| 18 | 30293703 | Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: Consensus opinion from a panel of experts. | Crit Rev Oncol Hematol | 2018 | https://conductscience.org/library/papers/30293703 | PubMed |
| 19 | 37137185 | New advances into cisplatin resistance in head and neck squamous carcinoma: Mechanisms and therapeutic aspects. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/37137185 | PubMed |
| 20 | 25058905 | Cisplatin in cancer therapy: molecular mechanisms of action. | Eur J Pharmacol | 2014 | https://conductscience.org/library/papers/25058905 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42410458 | Role of microRNAs in cisplatin response of cancer stem cells. | Stem Cell Res Ther | 2026 | https://conductscience.org/library/papers/42410458 | PubMed |
| 41511327 | Understanding the Tumor Microenvironment and Therapy Resistance in Head and Neck Squamous Cell Carcinoma. | Cells | 2025 | https://conductscience.org/library/papers/41511327 | PubMed |
| 41444987 | MicroRNAs as the critical regulators of ubiquitin-proteasome system through F-box protein targeting during tumor progression. | Cancer Cell Int | 2025 | https://conductscience.org/library/papers/41444987 | PubMed |
| 41388392 | Mechanistic study of HIF-1α-mediated regulation of the Notch1 pathway in promoting radioresistance in head and neck squamous cell carcinoma: a comprehensive analysis based on bioinformatics and functional experiments. | BMC Cancer | 2025 | https://conductscience.org/library/papers/41388392 | PubMed |
| 41226828 | MicroRNAs as Emerging Therapeutic Targets Modulating the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41226828 | PubMed |
| 40949794 | Role of VOPP1 in regulation of Paclitaxel response and EMT process during ovarian tumor progression. | Mol Biol Res Commun | 2025 | https://conductscience.org/library/papers/40949794 | PubMed |
| 40517336 | β-catenin as a key regulator of the cisplatin response in tumor cells. | Clin Exp Med | 2025 | https://conductscience.org/library/papers/40517336 | PubMed |
| 40508071 | Advances in Nanotechnology-Based Cisplatin Delivery for ORL Cancers: A Comprehensive Review. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40508071 | PubMed |
| 40025676 | Clinical Outcomes With Notch Inhibitors in Notch-Activated Recurrent/Metastatic Adenoid Cystic Carcinoma. | Cancer Med | 2025 | https://conductscience.org/library/papers/40025676 | PubMed |
| 39851970 | MicroRNA-129-3p Suppresses Tumor Progression and Chemoradioresistance in Head and Neck Squamous Cell Carcinoma. | Curr Oncol | 2025 | https://conductscience.org/library/papers/39851970 | PubMed |
| 39149512 | Exploring the nexus between MYH9 and tumors: novel insights and new therapeutic opportunities. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/39149512 | PubMed |
| 38956588 | MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma. | Mol Brain | 2024 | https://conductscience.org/library/papers/38956588 | PubMed |
| 38918809 | LncRNA MALAT1 facilitates BM-MSCs differentiation into endothelial cells and ameliorates erectile dysfunction via the miR-206/CDC42/PAK1/paxillin signalling axis. | Reprod Biol Endocrinol | 2024 | https://conductscience.org/library/papers/38918809 | PubMed |
| 38003016 | Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer. | Genes (Basel) | 2023 | https://conductscience.org/library/papers/38003016 | PubMed |
Genes147
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37587481
GET https://conductscience.org/api/papers/v1/37587481/references?page=2